Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Pediatrics
Erschienen in: Indian Journal of Pediatrics 4/2011

01.04.2011 | Symposium on Pediatric Tuberculosis

Latent Tuberculosis in Children: Diagnosis and Management

verfasst von: Meenu Singh, Arushi Gahlot Saini, Nidhi Anil, Amit Aggarwal

Erschienen in: Indian Journal of Pediatrics | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Control of tuberculosis in children often escapes attention because of the paucibacillary nature of the illness. However, they contribute much of the morbidity, mortality and future reservoir of the disease which reiterates the importance of risk-factor based screening for latent infection and appropriate treatment. We review the modalities and importance of diagnosis and treatment of latent tuberculosis infection in children. At this time, the role for interferon-gamma release assays in low-income, high-burden settings is rather limited but further research in the coming years might clear their role in children. An important emerging area of research is the development of an improved skin test for TB that uses specific mycobacterial antigens rather than tuberculin, thus is more feasible and useful in resource limited settings.
Literatur
1.
Amberson JB. The significance of latent forms of tuberculosis. N Engl J Med. 1938;219:572–6.CrossRef
2.
Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004;114:1175–201.CrossRef
3.
Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR Recomm Rep. 1994;43:1–132.
4.
Chugh S. Paediatric tuberculosis and DOTS strategy under RNTCP. J Indian Med Assoc. 2008;106:799–802.PubMed
5.
Working Group on Tuberculosis, Indian Academy Of Pediatrics (IAP). Consensus statement on childhood tuberculosis. Indian Pediatr. 2010;47:41–55.CrossRef
6.
Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med. 2006;173:1078–90.PubMedCrossRef
7.
Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax. 2006;61:616–20.PubMedCrossRef
8.
Dogra S, Narang P, Mendiratta DK, et al. Comparison of a whole blood interferon-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. J Infect. 2007;54:267–76.PubMedCrossRef
9.
Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev. 2007;8:124–33.PubMedCrossRef
10.
Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221–47.
11.
Enarson DA. Use of the tuberculin skin test in children. Paediatr Respir Rev. 2004;5:S135–7.PubMedCrossRef
12.
Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.PubMed
13.
Lighter J, Rigaud M, Eduardo R, Peng CH, Pollack H. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics. 2009;123:30–7.PubMedCrossRef
14.
Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet. 2004;364:2196–203.PubMedCrossRef
15.
Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis. 2007;45:322–8.PubMedCrossRef
16.
Zellweger JP. Latent tuberculosis: which test in which situation? Swiss Med Wkly. 2008;138:31–7.PubMed
17.
Ciaschetti A, Franchi A, Richeldi L, et al. Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test. G Ital Med Lav Ergon. 2007;29:406–7.PubMed
18.
Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med. 2008;149:777–87.PubMed
19.
Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest. 2009;135:1010–8.PubMedCrossRef
20.
Nakaoka H, Lawson L, Squire SB, et al. Risk for tuberculosis among children. Emerg Infect Dis. 2006;12:1383–8.PubMed
21.
Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361:1168–73.PubMedCrossRef
22.
Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis. 2004;38:966–73.PubMedCrossRef
23.
Hill PC, Brookes RH, Adetifa IM, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics. 2006;117:1542–8.PubMedCrossRef
24.
Nicol MP, Davies MA, Wood K, et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Pediatrics. 2009;123:38–43.PubMedCrossRef
25.
Pai M, O’Brien R. Tuberculosis diagnostics trials: do they lack methodological rigor? Expert Rev Mol Diagn. 2006;6:509–14.PubMedCrossRef
26.
Ranganathan S, Connell T, Curtis N. Interferon-gamma release assays in children–no better than tuberculin skin testing? J Infect. 2007;54:412–3.PubMedCrossRef
27.
Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing. Eur Respir J. 2007;29:1282–3.PubMedCrossRef
28.
Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics. 2009;123:419–24.CrossRef
29.
Arend SM, Franken WP, Aggerbeck H, et al. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis. 2008;88:249–61.PubMedCrossRef
30.
Nelson LJ, Jereb JA, Castro KG. New guidelines about latent tuberculosis infection in children and adolescents: a welcome advancement. Pediatrics. 2004;114:1084–6.PubMedCrossRef
31.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–51.
32.
Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med. 1961;265:713–21.PubMedCrossRef
33.
Comstock GW, Hammes LM, Pio A. Isoniazid prophylaxis in Alaskan Boarding schools. A comparison of two doses. Am Rev Respir Dis. 1969;100:773–9.PubMed
34.
Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.PubMed
35.
Stein MT, Liang D. Clinical hepatotoxicity of isoniazid in children. Pediatrics. 1979;64:499–505.PubMed
36.
O’Brien RJ, Long MW, Cross FS, Lyle MA, Snider Jr DE. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics. 1983;72:491–9.PubMed
37.
Finnell SM, Christenson JC, Downs SM. Latent tuberculosis infection in children: a call for revised treatment guidelines. Pediatrics. 2009;123:816–22.PubMedCrossRef
38.
Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997;155:1735–8.PubMed
39.
Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child. 1998;78:169–71.PubMedCrossRef
40.
Nakajo MM, Rao M, Steiner P. Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J. 1989;8:649–50.PubMed
41.
Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998;53:536–48.CrossRef
42.
Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9 month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715–22.PubMedCrossRef
43.
Magdorf K, Arizzi-Rusche AF, Geiter LJ, O’Brien RJ, Wahn U. Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood–a pilot project. Pneumologie. 1994;48:761–4.PubMed
44.
Prevention CDC. Update: Adverse event data and Revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003.
45.
Indian Academy of Pediatrics. Treatment of childhood tuberculosis: Consensus Statement of IAP Working Group. Indian Pediatr. 1997;34:1093–6.
Metadaten
Titel
Latent Tuberculosis in Children: Diagnosis and Management
verfasst von
Meenu Singh
Arushi Gahlot Saini
Nidhi Anil
Amit Aggarwal
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Indian Journal of Pediatrics / Ausgabe 4/2011
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-010-0295-7

Weitere Artikel der Ausgabe 4/2011

Indian Journal of Pediatrics 4/2011 Zur Ausgabe

Original Article

Aetiology and Antimicrobial Resistance of Neonatal Sepsis at a Tertiary Care Centre in Eastern India: A 3 Year Study

Symposium on Pediatric Tuberculosis

Multi-drug Resistant Childhood Tuberculosis

Scientific Letters to the Editor

Neonatal Tetanus Elimination in India—Still a Long Way to Go

Original Article

A Localized Case–Control Study of Extra-Gastric Manifestations of Helicobacter pylori Infection in Children

Clinical Brief

Spectrum of Kawasaki Disease

Commentary

Opportunistic Infections in HIV Infected Children

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

24.05.2024 Pränatale und perinatale Diagnostik Nachrichten

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise